General Introduction and Literature Review

Total Page:16

File Type:pdf, Size:1020Kb

General Introduction and Literature Review Identification and characterization of novel proteolytic interactions of prostate cancer- expressed kallikrein-related peptidases, type II transmembrane serine proteases and matrix metalloproteinases Janet C. Reid Bachelor of Science, Master of Science Qualifying, Graduate Diploma of Biotechnology Institute of Health and Biomedical Innovation Mater Medical Research Institute Translational Research Institute School of Biomedical Sciences, Queensland University of Technology A thesis submitted to the Queensland University of Technology in fulfillment of the requirements of a Doctor of Philosophy Jan 2015 Key Words Activity Based Probe (ABP), Calcium Signalling, Cell Surface, Hepatocyte Growth Factor (HGF), Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1), Kallikrein- Related Peptidase (KLK), Kidney Proximal Tubule Cells, Matrix Metalloproteinase (MMP), Prostate Cancer, Protease-Activated Receptor (PAR), Proteolytic Cascade, Recombinant Proteins, Serine Protease Inhibitor, Type II Transmembrane Serine Protease (TTSP). i Abstract In the tumour microenvironment pericellular proteolytic activity affects cells by cleavage of extracellular matrix proteins, activation of cell-surface receptors such as the protease activated receptors (PAR), and processing of mitogenic growth factors such as hepatocyte growth factor (HGF). As proteolysis is irreversible in physiological settings, protease activity is tightly regulated by a number of factors including localization, zymogen activation and protease inhibitors. However, overexpression of proteases in the dysregulated prostate cancer microenvironment has the potential to facilitate disease progression. The secreted serine proteases kallikrein-related peptidase (KLK)14 and KLK4 as well as the type II transmembrane serine proteases (TTSPs) hepsin and transmembrane protease serine 2 (TMPRSS2) have been implicated in the progression of prostate cancer as all four are upregulated this malignancy. For instance, increased KLK14 expression has been correlated with aggressive, late stage prostate cancer and decreased progression-free survival. KLK4 also has increased expression; however, this is seen in early stages of prostate cancer, with diminished KLK4 levels in late stages. Hepsin has also been implicated as expression increase through all prostate cancer stages to bone metastasis. Further, in a non-metastasising mouse model, hepsin overexpression has been implicated in invasion/extravasion and metastasis of primary prostate tumour cells through disorganisation of the basement membrane. TMPRSS2 also has increased expression in localized prostate cancer. Further, TMPRSS2 has dysregulated cellular localization in prostate cancer, moving from the apical cellular localization of normal epithelial prostate cells to the entire cell surface with intracellular accumulation in prostate cancer cells. Critically, KLK14, KLK4 and TMPRSS2 induce intracellular signalling pathways via proteolytic activation of PARs, and modulation of PAR- mediated signalling has been associated with cells acquiring a more cancerous phenotype. While hepsin and TMPRSS2 auto-activate, the endogenous activators of KLK14 and KLK4 are unknown. It was recently determined that matrix metalloproteinase MMP3 activates KLK4 in vitro and so may be an endogenous activator. Moreover, it is prostate expressed and has also been implication in the progression of several cancer types including prostate. In turn, MMP3 is activated by auto-activating TTSP family member ii matriptase, thereby potentially forming an activation cascade from matriptase to MMP3 to KLK4. As auto-activating proteases, hepsin and TMPRSS2 also have the potential to function in proteolytic activation cascades, activating either the KLKs or MMP3. In turn, the activated KLKs may induce PAR-mediated intracellular signalling or activate HGF, the MET receptor ligand. The goal of this study was to examine pericellular proteolytic activity. In particular, it focussed on proteolytic interactions of KLK14 and KLK4 with hepsin and TMPRSS2. To a lesser extent, interactions of hepsin and TMPRSS2 with MMPs, MMP3 and MMP9 were also examined. This study also examined HGF activation by KLK14 and KLK4, and inhibition of KLK14 by hepatocyte growth factor activator inhibitor-1 (HAI-1). Further, activation of PAR family members PAR1, PAR2 and PAR4 by KLK14, hepsin and matriptase, and PAR2 by KLK4, was examined. For the first part of this study recombinant pro-KLK14 was generated in insect cells and characterized. It was determined that while pro-KLK14 from this system is N- glycosylated, the protease produced by Cos-7 cells lack this modification. This indicates the potential for cell-type differential N-glycosylation of KLK14. Active recombinant KLK14 was also shown to activate pro-HGF, while KLK4 primarily degrades it. Examination of KLK14 inhibition by HAI-1A and HAI-1B isoforms indicated that this inhibitor is a KLK14 substrate rather than inhibitor as both isoforms were degraded by KLK14. In comparison, hepsin and HAI-1A formed the stable complexes characteristic of inhibition. The second part of this study examined the interactions between KLK4 and KLK14, the hepsin and TMPRSS2, and to a lesser extent matriptase, MMP3 and MMP9. The data from these studies suggest complex pericellular interactions between these proteases and can be summarized as follows: KLK4 and, to a lesser extent, KLK14 are proteolysed by hepsin and TMPRSS2, and the shortened forms of these KLKs were mainly detected in association with the cell Proteolysis of KLK4 by hepsin and TMPRSS2 does not appear to lead to activation; however, it is not known if cell-associated forms of KLK14 are activated by these TTSPs iii KLK4 cleaves the stem region of hepsin and TMPRSS2; however, these cleaved forms remain cell membrane-bound through disulphide links in the stem While KLK4 and KLK14 co-immunoprecipitate with hepsin and TMPRSS2, KLK14 and active KLK4 are located on the cell surface independently of these TTSPs MMP3 and MMP9 are activated by hepsin and TMPRSS2 (and matriptase) MMP3 and MMP9 co-immunoprecipitate with hepsin and TMPRSS2. The third and final part of the study focussed on PAR1, PAR2 and PAR4 activation by KLK14, matriptase and hepsin, as well as inhibition of KLK4 activation of PAR2 using the KLK4-specific inhibitor SFTI-FCQR. PAR2 activation by KLK4 was investigated further using human primary kidney proximal tubule cells (PTC), which have previously been described as co-expressing PAR2 and KLK4. It was determined that while KLK14 activated PAR1, PAR2 and PAR4, and matriptase activated PAR2-mediated signalling, in the form of intracellular Ca2+ mobilization, there was negligible activation of PAR1, PAR2 or PAR4 by hepsin. Further, KLK4 activation of PAR2 could be abrogated by the KLK4-specific inhibitor SFTI-FCQR. Interestingly, further examination of KLK4 activation of PAR2 showed that while it activates PAR2 in a number of cell types, it elicited minimal PAR2 activation and Ca2+ mobilization in human kidney PTCs. This data suggests cell-type biased agonism of PAR2 by KLK4 potentially initiating alternative intracellular signalling pathways, or alternatively, a KLK4 competitive substrate on the surface of these cells. In this final section LNCaP cells overexpressing hepsin or active site mutated hepsin were also generated as a tool to examine the participation of hepsin with other serine proteases in proteolytic cascades resulting in PAR activation. However, overexpression of hepsin in these cells resulted in minimal plasma membrane localization in contrast to catalytically inactive hepsin which readily localized to the plasma membrane. Importantly, this is the first report of KLK14 activation of pro-HGF. Further, this is the first time KLK14 degradation of HAI-1, and formation of hepsin-HAI-1 complexes, have been reported. It is also the first time cell-surface localization of KLK4 and KLK14 has been demonstrated. In addition, this is the first time active KLK4 has been isolated from the cell surface. iv The data in this study suggest that KLK14 may have a role in regulation of MET receptor/HGF signalling axis through HGF activation and degradation of key protease inhibitors, HAI-1A and HAI-1B. Further, the data set up the premise for a proteolytic cascade at the plasma membrane involving TMPRSS2 and hepsin activation of MMP3 and MMP9, with MMP3 then activating KLK4. Finally, the cell surface localization of KLK14 and KLK4 may facilitate activation of PARs, degradation of HAI-1 isoforms and pericellular activation of HGF. Based on the results of this study a number of exciting and interesting avenues have been proposed to further explore the role of KLK14, and these other prostate-expressed proteases, in modulation of the pericellular environment. v Table of Contents Key Words i Abstract ii Table of Contents vi List of Figures xi List of Tables xv List of Abbreviations xvi Publications contributed to during PhD xx Statement of Original Authorship xxi Acknowledgments xxii CHAPTER 1 INTRODUCTION AND LITERATURE REVIEW ------------------------ 1 1.1 Prostate cancer 2 1.2 Proteases 3 1.3 Serine proteases 5 1.4 Kallikrein-related peptidases (KLKs) 7 1.4.1 KLK4 11 1.4.2 KLK14 13 1.4.3 KLKs in proteolytic cascades 14 1.4.4 KLKs in prostate cancer 17 1.5 Type II transmembrane serine proteases (TTSPs) 19 1.5.1 Hepsin 21 1.5.2 TMPRSS2 22 1.5.3 Matriptase 24 1.5.4 TTSPs in proteolytic cascades 25 1.5.5 TTSPs in prostate cancer 26 1.6 Hepatocyte growth factor 28 1.7 Hepatocyte growth factor activator
Recommended publications
  • Haemostasis Antibodies from Cedarlane
    HAEMOSTASIS ANTIBODIES FROM CEDARLANE Haemostasis Antibodies www.cedarlanelabs.com Haemostasis Antibodies The study of haemostasis and thrombosis has become one of the most rapidly growing fields in medical research. An unprecedented amount of research is currently focused on the study of the regulatory mechanisms involved in blood clot formation, subsequent lysis, and potential pharmacological intervention of these processes. Cedarlane offers a complete line of antibodies to haemostasis related antigens. The high quality and purity of these antibodies make them valuable tools for applications including ELISA, immunohistochemistry, immunoblotting (Western blot) and immunoprecipitation techniques (including immunodiffusion and rocket immunoelectrophoresis). Haemostasis Antibodies Haemostasis NEW! Cedarlane offers an expanding range of new monoclonal antibodies to various haemostasis related antigens, providing customers a more comprehensive array of tools for the study of haemostasis and thrombosis. These antibodies have been tested for suitability for use in Western Blotting and ELISA. Featured Antibodies Specificity Format Clone Isotype Species Application Size Cat # Price $ Reactivity Factor VII/VIIA Purified AA-3 mouse IgG1 Human E, WB 200 μg CL2763AP 259 Factor VII/VIIA Biotin AA-3 mouse IgG1 Human E, WB 100 μg CL2763B 199 Factor VII/VIIa Purified AD-1 mouse IgG1 Human E, WB 200 μg CL2764AP 259 Factor VII/VIIa Biotin AD-1 mouse IgG1 Human E, WB 100 μg CL2764B 199 Factor VII/VIIa (Calcium Dependent) Purified CaFVII-22 mouse IgG1 Human
    [Show full text]
  • Functional Characterization of BC039389-GATM and KLK4
    Pflueger et al. BMC Genomics (2015) 16:247 DOI 10.1186/s12864-015-1446-z RESEARCH ARTICLE Open Access Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer Dorothee Pflueger1,2, Christiane Mittmann1, Silvia Dehler3, Mark A Rubin4,5, Holger Moch1,2 and Peter Schraml1* Abstract Background: Chimeric read-through RNAs are transcripts originating from two directly adjacent genes (<10 kb) on the same DNA strand. Although they are found in next-generation whole transcriptome sequencing (RNA-Seq) data on a regular basis, investigating them further has usually been refrained from. Therefore, their expression patterns or functions in general, and in oncogenesis in particular, are poorly understood. Results: We used paired-end RNA-Seq and a specifically designed computational data analysis pipeline (FusionSeq) to nominate read-through events in a small discovery set of renal cell carcinomas (RCC) and confirmed them in a larger validation cohort. 324 read-through events were called overall; 22/27 (81%) selected nominees passed validation with conventional PCR and were sequenced at the junction region. We frequently identified various isoforms of a given read-through event. 2/22 read-throughs were up-regulated: BC039389-GATM was higher expressed in RCC compared to benign adjacent kidney; KLK4-KRSP1 was expressed in 46/169 (27%) RCCs, but rarely in normal tissue. KLK4-KRSP1 expression was associated with worse clinical outcome in the patient cohort. In cell lines, both read-throughs influenced molecular mechanisms (i.e. target gene expression or migration/invasion) in a way that counteracted the effect of the respective parent transcript GATM or KLK4.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • An Overview of the Kallikrein Gene Families in Humans and Other Species: Emerging Candidate Tumour Markers૾
    Clinical Biochemistry 36 (2003) 443–452 An overview of the kallikrein gene families in humans and other species: Emerging candidate tumour markers૾ George M. Yousefa,b, Eleftherios P. Diamandisa,b,* aDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada bDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Abstract Kallikreins are serine proteases with diverse physiologic functions. They are represented by multigene families in many animal species, especially in rat and mouse. Recently, the human kallikrein gene family has been fully characterized and includes 15 members, tandemly localized on chromosome 19q13.4. A new definition has now been proposed for kallikreins, which is not based on function but, rather, on close proximity and structural similarities. In this review, we summarize available information about kallikreins in many animal species with special emphasis on human kallikreins. We discuss the common structural features of kallikreins at the DNA, mRNA and protein levels and overview their evolutionary history. Kallikreins are expressed in a wide range of tissues including the salivary gland, endocrine or endocrine-related tissues such as testis, prostate, breast and endometrium and in the central nervous system. Most, if not all, genes are under steroid hormone regulation. Accumulating evidence indicates that kallikreins are involved in many pathologic conditions. Of special interest is the potential role of kallikreins in the central nervous system. In addition, many kallikreins seem to be candidate tumor markers for many malignancies, especially those of endocrine-related organs. © 2003 The Canadian Society of Clinical Chemists. All rights reserved. Keywords: Kallikrein; Tumor markers; Cancer biomarkers; Prostate cancer; Breast cancer; Ovarian cancer; Alzheimer’s disease; Serine proteases; Chromosome 19; Kallikrein evolution; Rodent kallikreins; Hormonally regulated genes 1.
    [Show full text]
  • New Insights Into the Functional Mechanisms and Clinical Applications of the Kallikrein-Related Peptidase Family
    MOLECULAR ONCOLOGY 1 (2007) 269–287 available at www.sciencedirect.com www.elsevier.com/locate/molonc Review New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family Nashmil Emamia,b, Eleftherios P. Diamandisa,b,* aDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada bDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada ABSTRACT ARTICLE INFO Article history: The Kallikrein-related peptidase (KLK) family consists of fifteen conserved serine proteases Received 13 July 2007 that form the largest contiguous cluster of proteases in the human genome. While primar- Received in revised form ily recognized for their clinical utilities as potential disease biomarkers, new compelling 4 September 2007 evidence suggests that this family plays a significant role in various physiological pro- Accepted 7 September 2007 cesses, including skin desquamation, semen liquefaction, neural plasticity, and body fluid Available online 15 September 2007 homeostasis. KLK activation is believed to be mediated through highly organized proteo- lytic cascades, regulated through a series of feedback loops, inhibitors, auto-degradation Keywords: and internal cleavages. Gene expression is mainly hormone-dependent, even though tran- Kallikrein-related peptidases scriptional epigenetic regulation has also been reported. These regulatory mechanisms are PSA integrated with various signaling pathways to mediate multiple functions. Dysregulation of Proteolytic cascades these pathways has been implicated in a large number of neoplastic and non-neoplastic Skin desquamation pathological conditions. This review highlights our current knowledge of structural/ * Corresponding author. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.
    [Show full text]
  • Complete Amino Acid Sequence of Human Plasma Zn-A2-Glycoprotein and Its Homology to Histocompatibility Antigens
    Proc. Nati. Acad. Sci. USA Vol. 85, pp. 679-683, February 1988 Biochemistry Complete amino acid sequence of human plasma Zn-a2-glycoprotein and its homology to histocompatibility antigens (plasma protein structure/glycan structure//HLA dass I antigens/secretory major histocompatibility complex-related protein/immnnoglobuiln gene superfamily) TOMOHIRO ARAKI*, FUMITAKE GEJYO*t, KEIICHI TAKAGAKI*, HEINZ HAUPT*, H. GERHARD SCHWICKt, WILLY BURGI§, THOMAS MARTI¶, JOHANN SCHALLER¶, EGON RICKLI¶, REINHARD BROSSMER11, PAUL H. ATKINSON**, FRANK W. PUTNAMtt, AND KARL SCHMID*# *Department of Biochemistry, Boston University School of Medicine, Boston University Medical Center, Boston, MA 02118; *Behringwerke AG, 3550 Marburg/Lahn, Federal Republic of Germany; lZentrallaboratorium, Kantonsspital, 5001 Aarau, and lInstitut fOr Biochemie, University of Berne, 3012 Berne, Switzerland; IlDepartment of Biochemistry, University of Heidelberg Medical School, 6900 Heidelberg, Federal Republic of Germany; **Department of Developmental Biology and Cancer, Albert Einstein College of Medicine, Bronx, NY 10461; and ttDepartment of Biology, Indiana University, Bloomington, IN 47405 Contributed by Frank W. Putnam, September 22, 1987 ABSTRACT In the present study the complete amino acid like determinant in common with nephritogenic urinary sequence of human plasma Zn-a2-glycoprotein was deter- glycoproteins (2, 4). mined. This protein whose biological function is unknown In this paper we describe the determination of the com- consists of a single polypeptide chain of 276 amino acid plete amino acid sequence of Zna2gp, including the location residues including 8 tryptophan residues and has a pyroglu- of the two disulfide bridges and the structure of the three tamyl residue at the amino terminus. The location of the two carbohydrate units, and we discuss the possible secondary disuhlde bonds in the polypeptide chain was also established.
    [Show full text]
  • Cloning of a New Member of the Human Kallikrein Gene Family, KLK14, Which Is Down-Regulated in Different Malignancies
    [CANCER RESEARCH 61, 3425–3431, April 15, 2001] Cloning of a New Member of the Human Kallikrein Gene Family, KLK14, Which Is Down-Regulated in Different Malignancies George M. Yousef, Angeliki Magklara, Albert Chang, Klaus Jung, Dionyssios Katsaros, and Eleftherios P. Diamandis1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada [G. M. Y., A. M., A. C., E. P. D.]; Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario M5G 1LS, Canada [G. M. Y., A. M., A. C., E. P. D.]; Department of Urology, University Hospital Charite, Humboldt University, Berlin D-10098, Germany [K. J.]; and Department of Gynecologic Oncology, Institute of Obstetrics and Gynecology, University of Turin, Turin 10128, Italy [D. K.] ABSTRACT KLK gene locus and cloned a new gene, KLK14. Here, we describe the cloning of the new gene, its genomic and mRNA structure, its Kallikreins (KLKs) belong to the serine protease family of proteolytic precise location in relation to other known KLKs, and its tissue enzymes. Human pancreatic/renal KLK (KLK1) encodes for an enzyme expression pattern. KLK14 is highly expressed in tissues of the CNS that is involved in posttranslational processing of polypeptide precursors. The function of the other members of this gene family is currently including the brain, cerebellum, and spinal cord. Our preliminary unknown, but growing evidence suggests that many KLKs are implicated results suggest that this gene is down-regulated, at the mRNA level, in in carcinogenesis. By using the positional candidate approach, we were breast, testicular, ovarian, and prostate cancer. able to identify a new human KLK-like gene, KLK14 (also known as KLK-L6).
    [Show full text]
  • A Broad-Spectrum Humanlung Fibroblast-Derived Mitogen Is A
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 415-419, January 1991 Biochemistry A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor (heparin-binding growth factor/plasminogen/epithelial cells/endothelial ceils/melanocytes) JEFFREY S. RUBIN*, ANDREW M.-L. CHAN*, DONALD P. BOTTARO*, WILSON H. BURGESSt, WILLIAM G. TAYLOR*, ALEX C. CECH*, DAVID W. HIRSCHFIELD*, JANE WONG*, TORU MIKI*, PAUL W. FINCH*t, AND STUART A. AARONSON*§ *Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD 20892; and tLaboratory of Molecular Biology, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, MD 20855 Communicated by William H. Daughaday, October 10, 1990 (receivedfor review July 12, 1990) ABSTRACT A heparin-binding mitogen was isolated from Mitogenic Assays. DNA synthesis in the B5/589, BALB/ conditioned medium of human embryonic king fibroblasts. It MK, CCL208, and NIH 3T3 lines (10) and in primary exhibited broad target-cell specificity whose pattern was dis- melanocytes (11) was measured as described elsewhere. For tinct from that of any known growth factor. It rapidly stimu- proliferation assays (12), HUVECs were plated at 4 X 104 lated tyrosine phosphorylation of a 145-kDa protein in respon- cells per 6-cm tissue culture dish in basal medium (in the sive cells, suggesting that its signaling pathways involved presence or absence of heparin) supplemented with recom- activation of a tyrosine kinase. Purification identified a major binant aFGF or basic FGF (bFGF) (10 ng/ml) or HSAC- polypeptide with an apparent molecular mass of 87 kDa under purified, fibroblast-derived growth factor (-'100 ng/ml).
    [Show full text]
  • Table of Contents
    Table of Contents Preface V List of contributing authors VII Table of Contents XI Introduction to Volume 1: Kallikrein-related Peptidases. Characterization, Regulation, and Interactions Within the Protease Web 1 Bibliography 3 1 Genomic Structure of the KLK Locus 5 1.1 Introduction 5 1.2 Kallikreins in rodents 6 1.2.1 The mouse kallikrein gene family 7 1.2.2 The rat kallikrein gene family 8 1.3 Characterization and sequence analysis of the human KLK gene locus 9 1.3.1 Locus overview 9 1.3.2 Repeat elements and pleomorphism 11 1.4 Structural features of the human KLK genes and proteins 12 1.4.1 Common structural features 12 1.5 Sequence variations of human KLK genes 13 1.6 Regulation of KLK activity 14 1.6.1 At the mRNA level 14 1.6.2 Locus control of KLK expression 15 1.6.3 Epigenetic regulation of KLK gene expression 17 1.7 Isoforms and splice variants of human KLKs 18 1.8 Evolution of KLKs 21 Bibliography 22 2 Single Nucleotide Polymorphisms in the Human KLK Locus and Their Implication in Various Diseases 31 2.1 Introduction 31 2.2 KLK SNPs – data-mining from SNPdb and 1000 Genomes 32 2.3 Functional annotations using web-based prediction tools 34 2.4 Experimentally validated functional KLK SNPs 35 2.5 KLK SNP haplotypes and tagging 36 2.6 Malignant and non-malignant diseases and association with KLK SNPs 38 2.6.1 Association studies on high-risk variants in KLK genes 39 XII Table of Contents 2.6.2 Association studies on low-risk variants in KLK genes 39 2.7 Conclusions 71 Bibliography 71 3 Evolution of Kallikrein-related Peptidases 79
    [Show full text]
  • Aberrant Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Patients with Psoriasis: Dependence on Phenotype, Severity and Therapy N
    CLINICAL AND LABORATORY INVESTIGATIONS DOI 10.1111/j.1365-2133.2006.07743.x Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy N. Komatsu,* à K. Saijoh,§ C. Kuk,* F. Shirasaki,à K. Takeharaà and E.P. Diamandis* *Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada àDepartment of Dermatology and §Department of Hygiene, Graduate School of Medical Science, School of Medicine, Kanazawa University, Kanazawa, Japan Summary Correspondence Background Human tissue kallikreins (KLKs) are a family of 15 trypsin-like or Eleftherios P. Diamandis. chymotrypsin-like secreted serine proteases (KLK1–KLK15). Multiple KLKs have E-mail: [email protected] been quantitatively identified in normal stratum corneum (SC) and sweat as can- didate desquamation-related proteases. Accepted for publication 7 November 2006 Objectives To quantify KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13 and KLK14 in the SC and serum of patients with psoriasis, and their variation Key words between lesional and nonlesional areas and with phenotype, therapy and severity. diagnostic marker, human kallikreins, psoriasis, The overall SC serine protease activities were also measured. serine proteases, stratum corneum, therapy Methods Enzyme-linked immunosorbent assays and enzymatic assays were used. Conflicts of interest Results The lesional SC of psoriasis generally contained significantly higher levels None declared. of all KLKs. KLK6, KLK10 and KLK13 levels were significantly elevated even in the nonlesional SC. The overall trypsin-like, plasmin-like and furin-like activities were significantly elevated in the lesional SC.
    [Show full text]
  • Human Tissue Kallikrein Expression in the Stratum Corneum and Serum of Atopic Dermatitis Patients
    DOI:10.1111/j.1600-0625.2007.00562.x www.blackwellpublishing.com/EXD Original Article Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients Nahoko Komatsu1,2,3,4, Kiyofumi Saijoh4, Cynthia Kuk1, Amber C. Liu1, Saba Khan1, Fumiaki Shirasaki3, Kazuhiko Takehara3 and Eleftherios P. Diamandis1,2 1Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 3Department of Dermatology, Graduate School of Medical Science, School of Medicine, Kanazawa University, Kanazawa, Japan; 4Department of Hygiene, Graduate School of Medical Science, School of Medicine, Kanazawa University, Kanazawa, Japan Correspondence: Eleftherios P. Diamandis, MD, PhD, FRCPC, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5, Canada, Tel.: +1 416 586 8443, Fax: +1 416 586 8628, e-mail: [email protected] Accepted for publication 9 March 2007 Abstract: Human tissue kallikreins are a family of 15 trypsin- or differ significantly. In the serum of AD patients, KLK8 was chymotrypsin-like secreted serine proteases (KLK1–KLK15). Many significantly elevated and KLK5 and KLK11 were significantly KLKs have been identified in normal stratum corneum (SC) and decreased. However, their serum levels were not modified by sweat, and are candidate desquamation-related proteases. We corticosteroid topical agents. The alterations of KLK levels in the report quantification by enzyme-linked immunosorbent assay SC of AD were more pronounced than those in the serum. KLK7 (ELISA) of KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13 and in the serum was significantly correlated with eosinophil counts in KLK14 in the SC and serum of atopic dermatitis (AD) patients by the blood of AD patients, while KLK5, KLK8 and KLK11 were ELISA, and examine their variation with clinical phenotype, significantly correlated with LDH in the serum.
    [Show full text]
  • LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis
    C146-E340 LCMS Bioanalysis of Antibody Drugs Using Technical Fab-selective Proteolysis “nSMOL Method” Report — Selection of Signature Peptide — Noriko Iwamoto1, Takashi Shimada1 Abstract: nSMOL (nano-surface and molecular-orientation limited proteolysis) is Shimadzu's completely new, proprietary, and innovative technique for selective proteolysis of Fab region of monoclonal antibodies. nSMOL allows analytical method development of antibody drugs indepen- dent of a variety of antibody drugs. Fab-derived peptide fragments produced by nSMOL can be precisely quantified by multiple reaction monitoring (MRM) using the Shimadzu LCMS-8050/8060 triple quadrupole liquid chromatograph mass spectrometer (TQ-LCMS). This report describes a selection protocol of signature peptides suitable for pharmacokinetic studies. Keywords: nano-surface and molecular-orientation limited proteolysis, antibody drug, bioanalysis, LC/MS/MS 1. Introduction A peptide for quantitation (signature peptide) is selected from the tryptic peptides containing a complementarity-determining region Pharmacokinetic information provides some of the most fundamental (CDR), which defines the specificity of the antibody. However, it is not indicators. The effective drug discovery is supported by the overall possible that the CDR-containing peptide does not have the same pharmacokinetic profile such as for drug efficacy and toxicity. amino acid sequence as that in the endogenous IgGs. At this point, it must be confirmed that there is no competition with the signature The current method used for measuring drug concentration in blood peptide in the biological matrix. is enzyme-linked immunosorbent assay (ELISA). However, there are critical issues with ELISA, including influences from cross-reaction and inhibitory materials. In contrast, by MS, analysis is performed based on the structural information; thus, the aforementioned issues can 2.
    [Show full text]